Associate Professor Michael Barrett Jameson

Selected publications and creative works (Research Outputs)

  • Evans, S. O., Jacobson, G. M., Goodman, H. J. B., Bird, S., & Jameson, M. B. (2019). Comparative Safety and Pharmacokinetic Evaluation of Three Oral Selenium Compounds in Cancer Patients. Biological trace element research, 189 (2), 395-404. 10.1007/s12011-018-1501-0
    Other University of Auckland co-authors: Stephen Evans
  • Brian, T., McEwan, W., & Jameson, M. B. (2019). Sentinel node biopsy for melanoma: New Zealand indication guidelines in practice✰. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 72 (1), 137-171. 10.1016/j.bjps.2018.10.001
  • Lobb, R. J., Jacobson, G. M., Cursons, R. T., & Jameson, M. B. (2018). The Interaction of Selenium with Chemotherapy and Radiation on Normal and Malignant Human Mononuclear Blood Cells. International journal of molecular sciences, 19 (10).10.3390/ijms19103167
  • Brian, T., & Jameson, M. B. (2018). Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice. Journal of primary health care, 10 (3), 210-214. 10.1071/hc17055
  • So, Y., Anderson, M. C., Findlay, M. P. N., Gregory, K., Jackson, C., & Jameson, M. B. (2018). Investigating strategies to improve clinical trial opportunities in oncology in New Zealand (INSIGHT). JOURNAL OF CLINICAL ONCOLOGY. (pp. 1). 10.1200/JCO.2018.36.15_suppl.e18851
    Other University of Auckland co-authors: Michael Findlay
  • Jameson, M. B., Arendse, M., Pillai, A., Warren, J., Lolohea, S., & van Dalen, R. (2018). Final analysis of a randomized placebo-controlled double-blind phase II trial of perioperative cimetidine (CIM) in early colorectal cancer (CRC). JOURNAL OF CLINICAL ONCOLOGY. (pp. 2). 10.1200/JCO.2018.36.15_suppl.e15678
    Other University of Auckland co-authors: Avinesh Pillai
  • Maqsood, S., Jameson, M. B., De Groot, C., Hartopeanu, C., Yasin, N. A. B. H. M., & Thotathil, Z. (2018). Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status. Cancer Reports, 1 (1), e1001-e1001. 10.1002/cnr2.1001
  • McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., ... Xu, L. (2018). Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC. Targeted Oncology, 13 (1), 89-98. 10.1007/s11523-017-0543-0
    Other University of Auckland co-authors: Mark McKeage

Contact details

Primary office location

Level 0, Room 000
New Zealand